Filtered By:
Condition: Hypertension
Procedure: Heart Transplant

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 156 results found since Jan 2013.

Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
CONCLUSIONS: HIF stabiliser management of anaemia had uncertain effects on CV death, fatigue, death (any cause), CV outcomes, and kidney failure compared to placebo or ESAs. Compared to placebo or ESAs, HIF stabiliser management of anaemia probably decreased the proportion of patients requiring blood transfusions, and probably increased the proportion of patients reaching the target Hb when compared to placebo.PMID:36005278 | DOI:10.1002/14651858.CD013751.pub2
Source: Cochrane Database of Systematic Reviews - August 25, 2022 Category: General Medicine Authors: Patrizia Natale Suetonia C Palmer Allison Jaure Elisabeth M Hodson Marinella Ruospo Tess E Cooper Deirdre Hahn Valeria M Saglimbene Jonathan C Craig Giovanni Fm Strippoli Source Type: research

Diagnosis of Obstructive Sleep Apnea in Patients with Associated Comorbidity
Adv Exp Med Biol. 2022;1384:43-61. doi: 10.1007/978-3-031-06413-5_4.ABSTRACTObstructive sleep apnea (OSA) is a heterogeneous disease with many physiological implications. OSA is associated with a great diversity of diseases, with which it shares common and very often bidirectional pathophysiological mechanisms, leading to significantly negative implications on morbidity and mortality. In these patients, underdiagnosis of OSA is high. Concerning cardiorespiratory comorbidities, several studies have assessed the usefulness of simplified screening tests for OSA in patients with hypertension, COPD, heart failure, atrial fibril...
Source: Advances in Experimental Medicine and Biology - October 10, 2022 Category: Research Authors: F élix Del Campo C Ainhoa Arroyo Carlos Zamarr ón Daniel Álvarez Source Type: research

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Clonal Hematopoiesis and the Heart: a Toxic Relationship
AbstractPurpose of ReviewClonal hematopoiesis (CH) refers to the expansion of hematopoietic stem cell clones and their cellular progeny due to somatic mutations, mosaic chromosomal alterations (mCAs), or copy number variants which naturally accumulate with age. CH has been linked to increased risk of blood cancers, but CH has also been linked to adverse cardiovascular outcomes.Recent FindingsA combination of clinical outcome studies and mouse models have offered strong evidence that CH mutations either correlate with or cause atherosclerosis, diabetes mellitus, chronic kidney disease, heart failure, pulmonary hypertensi...
Source: Current Oncology Reports - March 15, 2023 Category: Cancer & Oncology Source Type: research

Cardiac transplant and exercise cardiac rehabilitation
AbstractCardiac transplantation is the final therapeutic option for patients with end-stage heart failure. Most patients experience a favorable functional ability post-transplant. However, episodes of acute rejection, and multiple comorbidities such as hypertension, diabetes mellitus, chronic kidney disease and cardiac allograft vasculopathy are common. The number of transplants has increased steadily over the past two decades with 3,817 operations performed in the United States in 2021. Patients have abnormal exercise physiologic responses related to surgical cardiac denervation, diastolic dysfunction, and the legacy of r...
Source: Heart Failure Reviews - April 4, 2023 Category: Cardiology Source Type: research

Artificial Intelligence for the Detection and Treatment of Atrial Fibrillation
AF, the most common clinically relevant cardiac arrhythmia, is expected to affect>5 million Americans by 2050.1 The diagnosis is frequently associated with other cardiovascular comorbidities, including hypertension, obesity and sleep apnoea, and AF is an important risk factor for stroke, heart failure and overall mortality.2 –4 Although treatment is available, many people remain untreated becau...
Source: Radcliffe Cardiology - April 19, 2023 Category: Cardiology Authors: c242508f1d9059bc0f2aa9bdd5421ba2 Source Type: research

Adrenomedullin peptides and precursor levels in relation to haemodynamics and prognosis after heart transplantation
ConclusionsElevated plasma levels of ADM may be a marker of pressure/volume overload in HF patients with PH, as well as long-term prognosis after HT. In line with previous studies, our findings additionally confirm that ADM may be a marker of venous congestion in HF. Further studies are encouraged to establish a deeper understanding of the properties of ADM and its relationship with HF and PH, in order to potentially facilitate clinical management of HF and associated PH.
Source: ESC Heart Failure - May 29, 2023 Category: Cardiology Authors: Abdulla Ahmed, Kriss Kania, Hebba Abdul Rahim, Salaheldin Ahmed, G öran Rådegran Tags: Original Article Source Type: research